Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Glaxosmithkline Plc (GSK) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 92,005,712
  • Shares Outstanding, K 2,437,770
  • Annual Sales, $ 36,578 M
  • Annual Income, $ 12,877 M
  • 36-Month Beta 0.90
  • Price/Sales 2.51
  • Price/Book 17.38

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.36 +0.83%
on 12/01/16
40.60 -7.22%
on 11/09/16
-0.96 (-2.49%)
since 11/04/16
3-Month
37.36 +0.83%
on 12/01/16
44.20 -14.77%
on 09/06/16
-6.59 (-14.89%)
since 09/02/16
52-Week
37.36 +0.83%
on 12/01/16
45.58 -17.35%
on 08/02/16
-2.60 (-6.46%)
since 12/04/15

Most Recent Stories

More News
Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed...

Merck: Keytruda's Priority Review for New Cancer Indication

Merck & Co., Inc.'s (MRK) yet another supplemental Biologics License Application for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

M Pharmaceutical Inc. Previews Business Strategy for Developing and Commercializing Prescription Strength C-103, Reformulated Orlistat

Glaxo (GSK) Files Regulatory Application for Shingrix in EU

Glaxo (GSK) announced that it has filed a Marketing Authorisation Application (MAA) in the EU for its shingles vaccine candidate, Shingrix.

Glaxo Nucala Favorable in Rare Vasculitis Disease Study

Glaxo's (GSK) Nucala hit co-primary endpoints and all secondary endpoints in a phase III study in patients with eosinophilic granulomatosis with polyangiitis.

Glaxo Files for COPD Drug; FluLaval Approved for Infants

GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) announced filing of a regulatory submission in the U.S. for a once-daily, closed triple combination therapy and received approval from the FDA for a...

Blog Coverage GlaxoSmithKline Files for US Approval for Triple Combination Lung Cancer Therapy

LONDON, UK / ACCESSWIRE / November 22, 2016 / Active Wall St. blog coverage looks at the headline from GlaxoSmithKline PLC (NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) as both companies announced on November...

GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple...

GSK files regulatory submission of candidate vaccine for prevention of shingles in Canada

GlaxoSmithKline Inc. (GSK) has submitted a New Drug Submission (NDS) for its candidate shingles vaccine, seeking approval for the prevention of herpes zoster (shingles) and its complications in Canadians...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Support & Resistance

2nd Resistance Point 37.98
1st Resistance Point 37.83
Last Price 37.67
1st Support Level 37.54
2nd Support Level 37.40

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.